EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche
Executive Summary
Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said
You may also be interested in...
Amgen Wins Supreme Court Review Of EPO Securities Fraud Class Certification
The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.
Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4
Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4